Applications published 7 November 2007

Novel propofol compsn comprising ascorbic acid or pharmaceutically acceptable salts thereof
Taro Pharmaceuticals; Dixit, Suresh; Goyal, Sandhya; Okech, Frederick; Shek, Efraim 1850829*

Method for the production of a preparation of a solid DMSO-containing silicone oil emulsion for the binding of reactive oxygen compounds in human and animal bodies
Exner, Heinrich 1850830*

Pharmaceutical aerosol formulations for pressurised metered dose inhalers comprising a sequestering agent
Chiesi Farmaceutici 1850831*

Adjuvanting material
Lipotek 1850832*

Formulations of substituted benzoxazoles
Wyeth 1850833*

Film-coated tablets containing ibuprofen lysinate
Boehringer Ingelheim International 1850834*

Oral pharmaceutical form of losartan
Flamel Technologies 1850835*

Method for a treatment with a medicament combination and medicament combinations suitable for the same
LTS Lohmann Therapie-Systeme 1850836*

• Use of morpholino compounds for the prevention of bacterial contamination
Sinclair Pharmaceuticals 1850837*

• Inhibition or treatment of dyskinesia
Proximagen 1850838*

• Methods for treating ocular angiogenesis, retinal oedema, retinal ischaemia and diabetic retinopathy using selective RTK inhibitors
Alcon 1850839*

• Novel compsns for preventing and treating neurodegenerative and blood coagulation disorders
Sirtris Pharmaceuticals 1850840*

• Methods for QT interval control
Janssen Pharmaceutica; Novack, Gerald; Truyen, Luc; Yuen, Eric; Chien, Shuchean 1850841*

• Pharmaceutical compsns comprising nebivolol and a hydrophilic polymer
Stada Arzneimittel 1850842*

• Inhibitors of AKT activity
Merck & Co 1850843*

• Spiro-containing compounds and compsns as modulators of steroid hormone nuclear receptors
IRM 1850844*

• Formulations and dosing regimen for PPAR-Alpha modulators
Eli Lilly 1850845*

• Compsn comprising a JNK inhibitor and cyclosporin
Laboratoires Serono 1850846*

• Inhibitors of checkpoint kinases
Merck & Co 1850847*

• Tetracyclic sulphonamide compounds and methods of use thereof
Inotek Pharmaceuticals 1850848*

• Method of preferentially inducing the biosynthesis of interferon
Coley Pharmaceutical 1850849*

• Compsns and methods for targeted delivery of immune response modifiers
3M Innovative Properties 1850850*

• Methods for treating cancer and other pathological proliferating disorders by inhibiting mitosis using pyrrolo[2,3-D]pyrimidines
Duquesne University of the Holy Ghost 1850851*

• Use of sildenafil, vardenafil and other 5-phosphodiesterase inhibitors to enhance permeability of the abnormal blood-brain barrier
Cedars-Sinai Medical Centre 1850852*

• Pharmacokinetically improved compounds
Surface Logix; Campbell, Stewart; Duffy, David; Gorgan, Michael; Kates, Steven; Ostuni, Emanuele; Schuller, Olivier; Sweetnam, Paul 1850853*

• Room temperature stable aqueous liquid pharmaceutical compsn
Biomarin Pharmaceutical 1850854*

• Compounds and uses thereof
CombinatoRx 1850855*

• Dosage and method for attaining beneficial levels of vitamin D3
Grote, James 1850856*

• Isolation of atraric acid, synthesis of atraric acid derivatives, and use of atraric acid and the derivatives thereof for the treatment of benign prostate hyperplasmia, prostate carcinoma and spinobulbar muscular atrophy
LTS Lohmann Therapie-Systeme 1850857*

• Polyethylene oxide polymers including anti-inflammatory glycoendrons
Emory University; University of California, San Diego 1850858*

• Pharmaceutically active phosphate binders, their manufacture, compsns containing them and their use
Ineos Healthcare 1850859*

• Prostate stem cell antigen vaccines and uses thereof
The Johns Hopkins University 1850860*

• Systemic treatment of infections with defensins
Novozymes 1850861*

• Method of treating disease with glycosylated interferon
Avigenics 1850862*

• Use of botulinum toxin for prolonged local desensitisation
Societe de Conseils de Recherches et d"Applications Scientifiques 1850863*

• New detoxification method
National Institute for Biological Standards and Control 1850864*

• Antilymphocyte antibody induction by combination of an S1P receptor agonist/modulator and of immunosuppressive drugs
Novartis 1850865*

• Therapeutic monoclonal antibodies that neutralise botulinum neurotoxins
The Regents of the University of California 1850866*

• Method of treating staphylococcus aureus infection
Nabi Biopharmaceuticals 1850867*

• Oral vaccines for fish
Plant Research International 1850868*

• Nucleic acid constructs
Powderject Vaccines 1850869*

• Compsn for adjuvant containing poly-gamma-glutamic acid
Biolenders 1850870*

• Adjuvant compsn comprising aluminium phosphate and 3D-MPL
Novartis Vaccines and DIagnostics 1850871*

• A method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
GTC Biotherapeutics 1850872*

• Antibodies to TGF-beta
Genzyme; Hart, Celia; Holgate, Robert; Jermutus, Lutz; Buchanan, Catriona; Duncan, Alexander; Finch, Donna 1850873*

• Extending time to disease progression or survival in cancer patients using a HER dimerisation inhibitor
Genentech 1850874*

• Sustained release compsn of protein drug
LG Life Sciences 1850875*

• Transport of nano- and macromolecular structures into cytoplasm and nucleus of cells
Ludwig-Maximilians-Universitaet Muenchen 1850876*

• Process for the preparation of alkoxyamine functionalised polyethylene glycols
Novo Nordisk 1850877*

• C-terminally PEGylated growth hormones
Novo Nordisk 1850878*

• Method of genotypically modifying cells by administration of RNA
Fischer Education Project 1850879*

• Apatamer therapeutics useful in the treatment of complement-related disorder
Archemix 1850880*

• Radiolabelled gallium complexes, methods for synthesis and use in PET Imaging of EGFR expression in malignant tumours
GE Healthcare 1850881*